$96.2 B

AZN Mkt cap, 16-Aug-2018

£22.5 B

AstraZeneca Revenue FY, 2017
AstraZeneca Gross profit (FY, 2017)18.1 B
AstraZeneca Gross profit margin (FY, 2017), %80.8%
AstraZeneca Net income (FY, 2017)2.9 B
AstraZeneca EBITDA (FY, 2017)6.7 B
AstraZeneca EBIT (FY, 2017)3.7 B
AstraZeneca Cash, 31-Dec-20173.3 B
AstraZeneca EV95.1 B

AstraZeneca Revenue

AstraZeneca revenue was £22.46 b in FY, 2017

Embed Graph

AstraZeneca Revenue Breakdown

Embed Graph

AstraZeneca revenue breakdown by business segment: 22.3% from Respiratory, Inflammation and Autoimmunity, 23.8% from Infection, Neuroscience and Gastrointestinal:, 15.9% from Oncology and 38.1% from Cardiovascular and Metabolic Diseases

AstraZeneca Income Statement

Annual

GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

5.4 b5.2 b5.5 b11.4 b12.1 b11.4 b11.1 b10.5 b11.5 b14 b13.5 b14.8 b19.8 b16.9 b19.6 b19.1 b23 b22.5 b

Revenue growth, %

1%(9%)(10%)

Cost of goods sold

2.2 b2 b2.2 b3.7 b3.7 b3.1 b2.8 b2.5 b2.8 b3.1 b2.7 b3.2 b4.1 b3.5 b4.3 b3.6 b4.1 b4.3 b

Gross profit

3.1 b3.2 b3.4 b7.6 b8.4 b8.3 b8.3 b8 b8.7 b10.8 b10.8 b11.6 b15.7 b13.4 b15.3 b15.5 b18.9 b18.1 b

Gross profit Margin, %

58%62%61%67%70%73%75%76%76%78%80%78%79%80%78%81%82%81%

Operating expense total

2.2 b2.2 b2.4 b5.9 b5.8 b5.6 b5.8 b5.7 b6.2 b7 b6.6 b7.6 b10 b11 b13.7 b12.4 b14 b14.5 b

Depreciation and amortization

4.6 b3.3 b2.9 b

EBITDA

4.9 b4.9 b7 b3 b4 b6.7 b

EBITDA margin, %

36%33%35%18%20%30%

EBIT

942 m1 b982 m1.7 b2.7 b2.7 b2.5 b2.3 b2.6 b3.8 b4.2 b4.1 b5.7 b2.4 b1.6 b3.2 b4.9 b3.7 b

EBIT margin, %

18%19%18%15%22%24%22%22%22%27%31%27%29%14%8%17%21%16%

Pre tax profit

975 m1.1 b1 b1.2 b2.6 b2.8 b2.5 b2.3 b2.7 b3.9 b4.4 b4 b5.4 b2.1 b921.4 m2.4 b3.6 b2.2 b

Income tax expense

(320 m)(345 m)(330 m)(502 m)(869 m)(762 m)(735 m)(639 m)(671 m)(1.1 b)(1.3 b)(1.2 b)(1.6 b)(457.7 m)(8.1 m)(188.2 m)(146 m)641 m

Net Income

655 m736 m715 m704 m1.7 b2.1 b1.8 b1.7 b2.1 b2.8 b3.1 b2.8 b3.8 b1.7 b913.3 m2.2 b3.4 b2.9 b

AstraZeneca Balance Sheet

Annual

GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

259 m303 m206 m265 m683 m489 m453 m409 m565 m2.9 b3.6 b2.9 b2.7 b6.1 b4.7 b4.8 b5 b3.3 b

Accounts Receivable

935 m969 m1.1 b1.8 b1.8 b1.7 b1.7 b1.8 b1.9 b2.2 b2.2 b2.7 b3.5 b3.6 b3.5 b3.6 b2.6 b2.8 b

Inventories

681 m728 m798 m1.3 b1.4 b1.7 b1.6 b1.7 b1.6 b1.3 b1.2 b1.1 b1 b1.3 b1.4 b1.7 b2.3 b3 b

Current Assets

3 b2.9 b2.7 b6.1 b7 b6.8 b7.6 b7.2 b7.7 b8 b8.7 b8.6 b10 b13.2 b12.2 b12.3 b13 b12.9 b

PP&E

1.9 b2.1 b2.4 b3.8 b3.3 b3.8 b4.1 b4.3 b4.5 b4.9 b3.8 b4.2 b4.4 b3.8 b4.4 b7.6 b10.3 b7.6 b

Goodwill

17.1 b24.1 b25.5 b30.4 b

Total Assets

5 b5 b5.5 b12.2 b12.3 b12.5 b13.5 b13.2 b13.7 b14.5 b15.3 b24.1 b29.4 b36.8 b43.3 b46.5 b62.5 b63.4 b

Accounts Payable

479 m529 m588 m997 m2 b1.7 b2 b1.7 b1.7 b1.8 b1.8 b1.8 b2.4 b1.6 b2.6 b2.7 b10.5 b11.6 b

Current Liabilities

1.9 b1.9 b2.1 b4.3 b4.6 b4.5 b5.1 b4.3 b4.2 b4 b4.8 b7.6 b8.4 b10.6 b12.8 b11.5 b15.3 b16.4 b

Non-Current Liabilities

1.1 b987 m893 m1.5 b1.3 b1.2 b1.4 b1.5 b1.8 b2.6 b2.6 b9 b11 b10.9 b16 b20.7 b32.4 b32 b

Total Debt

103 m76 m135 m126 m85 m75 m52 m69 m2.1 b102.3 m1.2 b144.9 m2.3 b2.2 b

Total Liabilities

3 b2.8 b3 b5.9 b6 b5.7 b6.5 b5.8 b6 b6.6 b7.5 b16.6 b19.4 b21.5 b28.8 b32.2 b47.7 b48.4 b

Additional Paid-in Capital

237 m237 m238 m274 m296 m302 m268 m236 m220 m230 m196 m183 m227.1 m207.1 m233.7 m244.7 m316 m317 m

Retained Earnings

311 m365 m315 m(61 m)(245 m)1.2 b1 b942 m1.2 b1.8 b2 b1.5 b2.1 b1.7 b(1.7 b)(511.2 m)3.3 b2.7 b

Total Equity

2 b2.2 b2.5 b6.4 b6.4 b6.8 b7 b7.4 b7.7 b7.9 b7.8 b7.4 b10 b15.3 b14.5 b14.3 b14.9 b15 b

Debt to Equity Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0.3 x0 x0.1 x0 x0.2 x0.2 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0.1 x0 x0 x0 x0 x0 x

Financial Leverage

2.5 x2.3 x2.2 x1.9 x1.9 x1.8 x1.9 x1.8 x1.8 x1.8 x2 x3.2 x2.9 x2.4 x3 x3.2 x4.2 x4.2 x

AstraZeneca Cash Flow

Annual

GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

655 m736 m715 m704 m1.7 b2.1 b1.8 b1.7 b2.1 b2.8 b3.1 b2.8 b3.8 b1.7 b913.3 m2.2 b3.4 b2.9 b

Cash From Operating Activities

1.1 b1.2 b1.2 b1.9 b2.8 b2.6 b3.5 b2.4 b3.2 b3.9 b3.9 b3.8 b5.5 b4.9 b5.2 b4 b4.1 b3.6 b

Dividends Paid

332 m365 m399 m764 m1.9 b850 m753 m754 m833 m976 m1.1 b1.3 b1.7 b2.6 b2.7 b

Cash From Financing Activities

(39 m)(32 m)(96 m)(112 m)(267 m)(665 m)(794 m)(811 m)(740 m)(2.7 b)(2.7 b)3 b(4 b)(2 b)(2 b)3.4 b(1.3 b)(2.9 b)

Net Change in Cash

101 m73 m112 m172 m428 m275 m14 m2 m165 m576 m1.1 b665 m(951.2 m)962.7 m(2 b)(28.7 m)(1.1 b)(1.7 b)

Income Taxes Paid

(457.7 m)(8.1 m)(179.7 m)(113.1 m)

AstraZeneca Ratios

GBPY, 2017

EV/EBITDA

14.2 x

EV/EBIT

25.9 x

EV/CFO

26.6 x

Revenue/Employee

367.7 k

Debt/Equity

0.2 x

Financial Leverage

4.2 x
Report incorrect company information

AstraZeneca Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016

Healthcare Workers

2.60 k3 k

Countries

100 100 100 100

Drugs Approved by FDA

1

Health Facilities Activated

250 403

NME in Late-stage Development

7 13 15 12

Phase I Trials Products

33 24 44 41

Phase II Trials Products

27 11 33 36

Phase III Trials Products

19 11 35 27

Projects in R&D Pipeline

99 133 146 132

Young Health Programme Members

1.40 m1.60 m
Report incorrect company information